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The identification of toxic A species and/or the process of
their formation is crucial for understanding the mechanism(s)
of A neurotoxicity in Alzheimer disease and also for the de-
velopment of effective diagnostic and therapeutic interven-
tions. To elucidate the structural basis of A toxicity, we de-
veloped different procedures to isolate A species of defined
size and morphology distribution, and we investigated their
toxicity in different cell lines and primary neurons. We ob-
served that crude A42 preparations, containing a monomeric
and heterogeneous mixture of A42 oligomers, were more
toxic than purified monomeric, protofibrillar fractions, or fi-
brils. The toxicity of protofibrils was directly linked to their
interactions with monomeric A42 and strongly dependent on
their ability to convert into amyloid fibrils. Subfractionation
of protofibrils diminished their fibrillization and toxicity,
whereas reintroduction of monomeric A42 into purified
protofibril fractions restored amyloid formation and enhanced
their toxicity. Selective removal of monomeric A42 from
these preparations, using insulin-degrading enzyme, reversed
the toxicity of A42 protofibrils. Together, our findings dem-
onstrate that A42 toxicity is not linked to specific prefibrillar
aggregate(s) but rather to the ability of these species to grow
and undergo fibril formation, which depends on the presence
of monomeric A42. These findings contribute significantly to
the understanding of amyloid formation and toxicity in Al-
zheimer disease, provide novel insight into mechanisms of A
protofibril toxicity, and important implications for designing
anti-amyloid therapies.
Aggregation of amyloid- (A)2 peptides and deposition
into neuritic plaques are hallmark features of Alzheimer dis-
ease (AD) neuropathology (1, 2). Therefore, research efforts
during the past 3 decades have focused on elucidating the
mechanisms of A fibrillization, identifying toxic species, and
developing strategies to inhibit and/or reverse A amyloid
formation and toxicity in vivo (3, 4).
A peptides are produced as soluble monomers (5, 6) and
undergo oligomerization and amyloid fibril formation via a
nucleation-dependent polymerization process (7, 8). During
the course of in vitro A fibril formation, various nonfibrillar
aggregation intermediates, collectively called soluble olig-
omers or protofibrils, have been shown to precede the emer-
gence of fibrils. Increasing evidence from various sources
points to A oligomers/protofibrils as putative toxic species
in AD pathogenesis and suggests that these species are poten-
tial therapeutic targets for treating AD (reviewed in Refs. 9,
10). Although the toxic oligomer hypothesis has emerged as
one of the major current working hypotheses in AD research,
the development of effective diagnostic tools and therapies
on the basis of this hypothesis has yet to be realized (11–13).
This is partially due to the fact that identification of a single
toxic A species that correlates with AD progression and se-
verity remains elusive. Furthermore, the exact mechanisms by
which these species contribute to A toxicity in vivo and the
nature of the toxic species are not yet fully understood. Re-
cent evidence suggests that accelerating the process of A
fibrillization greatly enhances A toxicity in vitro (14) and the
spread of amyloid pathology in vivo (15–17).
Despite significant efforts by different groups to isolate spe-
cific intermediates along the amyloid formation pathway (12,
18–22), the inherent heterogeneity of the process and meta-
stable nature of A oligomers (11–13) have precluded the
isolation of a single toxic species. Unless covalently cross-
linked (23), A oligomers do not exist as stable entities, i.e.
they evolve into higher order aggregates and, if they are on-
pathway intermediates, convert into fibrils (19). Therefore, it
is plausible to assume that the structural dynamics of olig-
omers and factors that govern their interconversion and/or
growth might influence some of the disease-related cytotoxic
effects of A. In other words, an ongoing polymerization
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process involving the elongation and growth of oligomers,
rather than the formation of a stable oligomeric species, may
be responsible for A toxicity and neurodegeneration in AD.
To test this hypothesis, we developed different procedures
to isolate A species of defined size and morphology distribu-
tion (24), and we investigated their toxicity in different cell
lines and primary neurons. We observed that crude A42
preparations, containing a monomeric and heterogeneous
mixture of A42 oligomers and protofibrils, were more toxic
than the purified monomeric protofibrillar fractions or fibrils.
The toxicity of protofibrils was directly linked to their interac-
tions with monomeric A42 and strongly dependent on their
ability to convert into amyloid fibrils.
Selective removal of the monomers, by SEC or by degra-
dation with insulin-degrading enzyme (IDE), retarded the
elongation of protofibrils, their fibrillization, and dimin-
ished protofibril toxicity toward cultured rat primary neu-
rons, pheochromocytoma (PC12) cells, and neuroblastoma
(SHSY5Y) cells. Similarly, we show that an ongoing A42
polymerization process, rather than distinct A42 aggregate
states, also underlies previously reported alterations in astro-
cyte metabolic phenotypes (25). These findings contribute
significantly to the understanding of amyloid formation and
propagation in AD, provide novel insight into the mecha-
nisms of A protofibril toxicity, and carry important implica-
tions for designing anti-amyloid therapies.
EXPERIMENTAL PROCEDURES
Unless indicated otherwise, chemicals and reagents of ana-
lytical grade were purchased from Sigma. A peptides were
synthesized and purified by Dr. James I. Elliott, Yale Univer-
sity, New Haven, CT, as described previously (26). Chroma-
tography columns (Table 1) were purchased from GE Health-
care except TSK-GEL G4000 PWXL (TSK4000), which was
purchased from Tosoh Bioscience (Belgium). Highly purity
distilled water was used to prepare buffers, and solutions were
filtered and degassed by passing through vacuum-driven
0.22-m stericup filtration units (Millipore, Switzerland) be-
fore use. Deoxy-D-glucose (2-[1,2-3H]glucose (2-[3H]DG),
specific activity, 30–60 Ci/mmol) was obtained from
ANAWA (Switzerland). DNase and papain were purchased
from Sigma (catalog no. D4527 and P4762, respectively).
Preparation of A42 Protofibrils
Crude A42 protofibril (A42 CR) solution was prepared
as described previously (24, 27). Briefly, 1 mg of lyophilized
A42 was solubilized in 50 l of 100% anhydrous DMSO in a
1.5-ml sterile microtube. Then 800 l of high purity water
was immediately added, and the pH was brought to7.6 by
adding 10 l of 2 M Tris base, pH 7.6. The solution was always
freshly prepared and used immediately.
Size Exclusion Chromatography
Separation of A Protofibrils and Monomers—SEC frac-
tionation was carried out using an A¨KTA Explorer FPLC (GE
Healthcare) placed inside a cold (4 °C) chamber. SEC columns
were thoroughly equilibrated with SEC running buffer (10 mM
Tris-HCl, pH 7.4) prior to A injections. A (40 and 42)
monomers and A42 protofibrils were obtained by SEC as
described previously (24, 27). To prepare Amonomers, 1 mg
of lyophilized A was dissolved in 1 ml of 6 M guanidine HCl
solution and subsequently centrifuged (16,000 g, 4 °C, 10
min). The supernatant was injected into a Superdex 75 HR
10/30 column, and A was eluted at flow rate of 0.5 ml/min (1
ml/fraction). A elution was monitored at absorbance wave-
lengths of A210, A254, and A280. To obtain both protofibrils
(PF) and monomers (M), A42 crude (CR) solution was pre-
pared as described above. After centrifugation (16,000 g,
4 °C, 10 min), the supernatant was fractionated on a Superdex
75 column as described above. The fractions eluting in the
void volume were combined and labeled as protofibrils,
whereas the fractions eluting under the 11–13-ml peak were
combined and labeled as monomers. The PF and M fractions
were further characterized by thioflavin-T (ThT) binding and
transmission electron microscopy (TEM) as described below
and used immediately for analytical SEC and toxicity studies.
Subfractionation of A42 Protofibrils—A CR solution was
prepared and centrifuged as described above. The superna-
tant was injected into either a single SEC column with a
higher molecular weight separation range than Superdex 75
or a combination of SEC columns connected in series (Table
1) and fractionated as described above. For experimental pur-
poses, the fractions corresponding to monomeric elution
were combined. However, the fractions corresponding to
protofibrillar fractions were kept separate and labeled accord-
ing to their elution position (Table 1). The fractions were fur-
ther characterized by ThT binding and TEM and used imme-
diately for analytical SEC and toxicity studies.
A Concentration Determinations—A concentration in
fractions was determined by UV absorbance at 280 nm (A280)
using the theoretical molar extinction coefficient 1490 M1
cm1 (28).
Preparation of Fibrils and Sonicated Fibrils—A42 F were
prepared by incubating the CR solution (200 M) at 37 °C
with gentle shaking for 24–48 h. Fibril formation was con-
firmed by ThT binding and TEM. To generate fibril seeds
(SF), 100–300-nm-long fibrillar structures, the fibrils were
sonicated on ice using a Vibra-CellTM instrument (Sonics and
Materials, Inc.) equipped with a fine tip (five times, 20-s
pulses, amplitude 40%, output watts 6, 20-s delay between
successive pulses). Subsequently, the quality of SF preparation
and fibril fragmentation was confirmed by TEM.
Analytical SEC (Ana-SEC)—Ana-SEC was carried out to
assess the efficiency of fractionation and heterogeneity in
TABLE 1
SEC fractionation of A protofibrils andmonomers
Serial no. SEC column
Separation
range
PF
fractions
M
fractions
kDa
1. Superdex 75 HR 10/30 3–70 1a 1a
2. Superdex 200 GL 10/300 10–600 4, 5 1a
3. Superose 6 HR 10/30 5–5000 4–6 1a
4. TSK-GEL G4000PWXL 10–1500 3, 4 1a
5. Superdex 75 CISb Superose 6 6–8 1a
6. TSK-GEL G4000PWXL CISb
Superose 6
6–8 1a
a The fractions were combined.
b CIS means connected in series.
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each of the purified protofibrillar fractions. For this purpose,
an analytical SEC column Superose 6 pc 3.2/30 was connected
to a Waters Separation Module 2795 equipped with a photo-
diode array detector (Waters). Aliquots (50 l) of the A frac-
tions were injected into the column and eluted at flow rate of
0.05 ml/min. A elution was monitored at UV A210, A254,
and A280.
Cell Culture Toxicity Studies
Primary Neuronal Cell Cultures—Primary cortical neurons
were prepared from Sprague-Dawley rats (Charles River Lab-
oratories, L’Arbresle, France) at postnatal day 1 essentially as
described previously (29). After removing the meninges, the
cortical tissue was cut into small pieces and enzymatically
disrupted in dissociation buffer (papain, CaCl2, EDTA, and
HEPES; 30 min; 37 °C). The DNase was added for 10 min.
Cortex pieces were then washed three times in prewarmed
complete growth medium (neurobasal 10% FCS penicil-
lin/streptomycin L-glutamine; Invitrogen) and then tritu-
rated seven times in 5 ml of medium. Cells were filtered
through a 0.45-m cell strainer, counted, and plated onto
96-well, poly-L-lysine-precoated plates (30,000 cells/200 l/
well). After 90 min of incubation at 37 °C, the medium was
replaced by astrocyte-conditioned growth medium. On the
4th day in vitro (DIV 4), 2.5 M cytarabine (Sigma) was added.
Rat Pheochromocytoma (PC12) and Human Neuroblastoma
(SHSY5Y) Cell Cultures—PC12 cells were cultured in DMEM
(Invitrogen 41966-029) supplemented with 1% penicillin/
streptomycin (Invitrogen) and 2 M human recombinant in-
sulin (Invitrogen). The cells were plated in 96-well transpar-
ent BD Falcon plates (30,000 cells/200 l/well) and allowed to
grow in a cell culture incubator (37 °C; ambient humidity; 5%
CO2) for 24–48 h. SHSY5Y cells (40,000 cells/100 l/well)
were cultured in a similar fashion as PC12.
A Toxicity Studies in Primary Neuronal Cultures
Primary neurons were treated with the following A42
preparations: 1) A42 crude; 2) A42 fibrils; 3) SEC purified
protofibrils and monomers; and 4) 1:1 molar mixtures of
protofibrils and monomers. For this purpose, on DIV 7 half of
the culture medium was replaced by complete growth me-
dium containing A preparations (0.2 (v/v) medium dilution;
A preparations and the buffer vehicle contained 140 mM
NaCl and 10 M final A concentration). After 24 h of treat-
ment, neuronal cell viability was assessed by 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduc-
tion assay as described below.
A Toxicity Studies in PC12 and SHSY5Y Cell Cultures
Toxicity of A42 Crude, Fibrils, Protofibrils, andMonomers—
After 24–48 h in culture, half of the culture medium was re-
moved and replaced with the indicated A preparations. For
this purpose, A preparations were added to the supple-
mented 10 DMEM (Table 2) at a 9:1 (v/v) ratio. PC12 and
SHSY5Y cells were treated with final A concentration of
10 M. After 24 h of treatment, cell viability was assessed by
MTT reduction assay. Medium aliquots were obtained for
ThT binding and TEM.
Toxicity of A42 Protofibril/Monomer Mixtures and Proto-
fibril/Fibril Mixtures—Mixtures of SEC-purified A42 mono-
mers, protofibrils fractions (Table 1), and sonicated fibrils
were prepared in supplemented 10 DMEM (Table 2).
Briefly, the following mixtures were prepared (molar ratios):
1) protofibrils and monomers (1:1); 2) protofibrils and soni-
cated fibrils (4:1); 3) monomers and sonicated fibrils (4:1); 4)
protofibrils, monomers, and sonicated fibrils (2:2:1); and 5)
protofibrils and monomers, and the monomers were incu-
bated with insulin-degrading enzyme (R & D Systems catalog
no. 2496-ZN) for 20 min at room temperature (A: recombi-
nant human IDE, 20:1) and then added to protofibrils. PC12
and SHSY5Y cells were treated with mixtures 1–5 (final A
concentration of10 M), and after 24 h, viability was as-
sessed by MTT reduction assay. Medium aliquots were ob-
tained for ThT binding and TEM.
Time Course of A42 Toxicity—PC12 cells were cultured in
phenol red-free DMEM (Invitrogen catalog no. 21063-029)
supplemented with 1% penicillin/streptomycin (Invitrogen)
and 2 M human recombinant insulin (Invitrogen). PC12 cells
were treated with 10 M A42 crude solution. Medium ali-
quots were obtained at selected time points and analyzed by
ThT binding and TEM. In parallel, cell viability was assessed
by MTT reduction and lactate dehydrogenase release in the
media as described below.
Cell Viability Assays
MTT Reduction Assay—The viability of A-treated cells
was assessed by MTT reduction assay using a commercial kit
(Promega, catalog no. G4000) according to the manufacturer’s
instructions. The absorbance was measured at 570 nm
(690 nm was used as a reference wavelength) in a Safire2 mi-
croplate reader (TECAN). The signal was expressed as per-
centage of the A570–690 count from the vehicle-treated cells
(100%).
Lactate Dehydrogenase Release Assay—The lactate dehy-
drogenase release assay was carried out on medium aliquots
using a commercial kit (Sigma TOX-7) according to the man-
ufacturer’s instructions. The lactate dehydrogenase content
in the medium of the vehicle treated cells was expressed as
100%.
Primary Astrocyte Cell Cultures—Primary cortical astrocyte
cultures were prepared as established previously using 1–2-
day-old Swiss Albino mice (OF1, Charles River Laboratories)
(25). After removing the meninges, cortices were isolated and
dissociated by passage through needles of decreasing gauges
TABLE 2
Supplemented 10 DMEM for delivery of A fractions for toxicity
assays
Serial no. Component (stock) Volume Concentration
l
1. DMEM (10, Sigma D2429) 690
2. L-Glutamine (200 mM) 200 40 mM
3. Insulin (690 M) 30 20.7 M
4. Glucose (5 M) 40 250 mMa
5. Folic acid (2.25 mM) in NaHCO3
(11 M)
40 90 and 440 mM,
respectively
Total volume 1000 l
a Sigma 10 DMEM already contains 10 g/liter glucose. Therefore, more glucose
is added in order to bring the concentration to 45 g/liter (250 mM).
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(1.2 40 mm, 0.8 40 mm, and 0.5 16 mm) using a 10-ml
syringe. Cells were seeded on polyornithine-coated 35
10-mm culture dishes in growth medium (Dulbecco’s modi-
fied Eagle’s medium (DMEM), Sigma catalog no. D7777, sup-
plemented with 10% fetal calf serum, 44 mM NaHCO3, and 1%
antibiotic/antimycotic solution (Invitrogen)) and incubated
(37 °C; 5% CO2, 95% air). On DIV 5, the medium was renewed
with fresh medium and then renewed twice a week until use.
On DIV 21, cells were treated for 24 h with A preparations
(in 10 mM Tris-HCl, pH 7.4) diluted in the growth medium
(0.2 (v/v) dilution), for 24 h. 2-[3H]DG utilization (uptake and
phosphorylation) by A-treated cells was assessed as outlined
below.
2-[3H]DG Utilization—2-[3H]DG utilization experiments
were conducted as described previously (25). The media used
for 2-[3H]DG uptake were pre-equilibrated at 37 °C, 5% CO2
and 95% air. To initiate the 2-[3H]DG assay, the medium was
replaced by 2 ml of serum-free medium (DMEM (D5030,
Sigma) supplemented with 5 mM glucose, 44 mM NaHCO3,
and 1% of antibiotic/antimycotic solution) containing 1
Ci/ml 2-[3H]DG. The cells were incubated for 20 min at
37 °C, 5% CO2 and 95% air. The assay was terminated by aspi-
ration of the culture medium and washing the cells three
times with 4 ml of ice-cold PBS. Cells were then lysed by add-
ing 2 ml of 10 mM NaOH containing 0.1% Triton X-100. Then
500-l aliquots, in duplicates, were assayed for radioactivity
using liquid scintillation counting. The results were calculated
by subtracting from the total counts the portion that was not
inhibited by the glucose transporter inhibitor cytochalasin B
(25 M), which was added 20 min prior to and along the
2-[3H]DG incubation. 2-[3H]DG utilization was calculated as
femtomoles per dish and then expressed as percentage of the
vehicle control.
ThT Binding Assay—ThT binding assay was performed by
mixing 80 l of A preparations (in SEC buffer or cell culture
media) with 20 l of ThT (100 M) and 10 l of glycine-
NaOH, pH 8.5 (500 mM), in a Nunc 384-well fluorescence
plate (100 l/well). The ThT fluorescence of each sample was
measured in an Analyst AD fluorometer (Molecular Devices,
Switzerland) at excitation and emission wavelengths of
450 nm and 485 nm, respectively.
TEM Sample Grid Preparation and Image Acquisition—A
5–10-l droplet of sample containing A (A preparations or
cell culture media) was deposited on a 200 mesh Formvar-
coated TEM grid (EM Sciences) and was allowed to settle for
60 s. The excess solution was wicked away by gently apply-
ing a piece of blotting paper to the edge of the grid. Then a
10-l droplet of 2% uranyl acetate was deposited on the grid
and allowed to settle for60 s. The excess solution was re-
moved as above. Finally, the grid was vacuum-dried by gently
applying the vacuum probe close to the grid edges. Image ac-
quisition was carried out using a Phillips CM10 microscope
operated at an acceleration voltage of 80 kV.
RESULTS
SEC Subfractionation Retards Elongation of Protofibrils and
Decreases Toxicity—We and others have shown that toxic A
protofibril preparations consist of a heterogeneous mixture of
high molecular weight aggregates of various sizes and mor-
phologies (12, 24, 30). To determine whether the cytotoxicity
of protofibrils is associated with specific type of aggregates or
depends on the dynamics of inter-conversion among different
aggregate species, we subjected a crude A42 protofibril
preparation (A42 CR) to fractionation by SEC (12, 24). Then
we investigated the cellular toxicity of individual A42 frac-
tions, enriched with distinct protofibrillar aggregates, using
cultured PC12 and SHSY5Y cells. Subfractionation of A42
protofibrils on a Superose 6 column resulted in 4–6 fractions
corresponding to the elution of protofibrils (Fig. 1A). Only the
first four protofibril fractions (F1–F4) had sufficient A con-
tent (25 M) to be useful for toxicity experiments. The
monomers eluted later in two fractions (F5 and F6) that were
separate from protofibrils (Fig. 1A). Reinjection of the purified
A species onto an Ana-SEC column showed that only F1 and
F4 exhibited distinct elution profile for the protofibril peak,
suggesting marked differences in the size distribution of the
aggregates in these fractions (Fig. 1B). Soon after SEC frac-
tionation, F1 consisted of large aggregates and clusters of
protofibrils (Fig. 1F), whereas F3 was predominantly enriched
with short curvilinear and spherical protofibrils (Fig. 1G). The
monomer fraction (F5) was devoid of any visible aggregates
(Fig. 1H). Ana-SEC of the monomer fractions (F5 and F6)
showed a single narrow elution peak (data not shown).
Cell viability assessments of A-treated cultured PC12 and
SHSY5Y cells revealed that crude A42 protofibrils (CR) de-
creased viability by40–45% (p 0.01), whereas the toxicity
of A42 SEC fractions (protofibrils and monomers) did not
exceed10–20% (Fig. 1C). A40 monomers were also tested
as control and consistently showed only a slight, but not sig-
nificant, effect on the cell viability (5–10%, p 0.05; Fig.
1C). To determine whether the observed toxicity correlated
with the changes in A42 aggregation state in individual frac-
tions, we sampled the cell culture medium at different time
points and probed the aggregation state of A using ThT and
TEM. Only the crude protofibrils exhibited a significant and
gradual rise in ThT binding and reached a maximum within
24–48 h. In contrast, none of the purified protofibril fractions
(F1–F4) showed a comparable rise in ThT signal even after
96 h of incubation. ThT binding by the monomer fraction
(F5), after 96 h of incubation, did not exceed that of the proto-
fibrils (Fig. 1D).
On the basis of these observations, we hypothesized that
the loss of fibrillization led to attenuation of A toxicity and
that the toxicity in crude A42 protofibrils (CR) was medi-
ated by an ongoing process of A polymerization rather than
the formation of specific/stable aggregation state(s). In sup-
port of this hypothesis, analysis of the culture medium by
TEM revealed that only the crude A42 protofibrils (CR)
formed extensive mature fibrils (1 m long and high ThT
binding) during the course of the experiments (Fig. 1I). Even
after 96 h of incubation, mature fibrils were not observed in
culture medium containing the purified protofibril fractions
F1 and F3 (Fig. 1, J and K, respectively). Instead, clusters of
elongated curvilinear protofibrils were observed. The mono-
mer fraction (F5) did show some fibril-like structures (Fig.
1L), but they were not as extensive as those seen in the case
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of the crude A42 protofibrils (Fig. 1I). Subsequent sub-
fractionation experiments, using combinations of SEC col-
umn connected in series (Table 1), confirmed these find-
ings and revealed that the fibrillization and toxicity of
crude A42 protofibrils were closely linked processes (supple-
mental Figs. 1 and 2).
Separation of Monomers from Protofibrils Retards A42
Fibril Formation and Reduces the Toxicity of Protofibrils—
Some of the possible explanations for the reduced fibrilli-
zation and toxicity of A42 protofibrils upon SEC subfrac-
tionation include the following: 1) the presence of a small
number of fibrils in the crude preparations that are lost
upon SEC fractionation; 2) disruption of the structure of
toxic A species upon interaction with the SEC column
matrices; 3) disruption of the dynamics of inter-conversion
among different protofibril species; or 4) retardation of
protofibril growth due to the removal of excess free A
monomers. To investigate these possibilities, we compared
the aggregation and toxic properties of crude A protofi-
brils (CR) with those of monomers (M), fibrils (F), and the
protofibrils (PF) that were not subfractionated and simply
separated from monomers. When A42 CR was fraction-
ated on a Superdex 75 SEC column, all protofibrils eluted
in the void volume without further separation (cutoff 70
kDa) and monomers eluted later in the included volume
(Fig. 2A), as reported previously (27, 30). We have verified
that these conditions yield protofibrils andmonomer fractions
that are free of fibrils (24). The PF fraction contains a hetero-
geneous mixture of different quaternary structures. Cell via-
bility assessments of A-treated primary neuron cultures,
PC12 cells, and SHSY5Y cells revealed that 24 h of treatment
with A42 CR decreased the viability of PC12 and SHSY5Y
cells by40% (p 0.01) and of primary neurons by50%
(p 0.01) (Fig. 2C). The purified, but not subfractionated, PF
decreased cell viability by20–30% (p 0.05), and A42 M
exhibited only a slight effect (5–20%, p 0.05) (Fig. 2C).
FIGURE 1. Fibril formation and toxicity of subfractionated A42 protofibrils. A, subfractionation of A42 protofibrils (F1–F4) and isolation of monomers
(F5 and F6) on a Superose 6 SEC column. B, analytical SEC of protofibrillar fractions (F1–F4) on a Superose 6 pc 3.2/30 column. C, cell viability (MTT reduction
assay) of cultured PC12 and SHSY5Y cells after 24 h of treatment with 10 M A42 CR protofibrils, protofibrils fractions (F1–F4), and monomers (F5) (one-
way ANOVA, n 9, *, p 0.05; **, p 0.01, mean	 S.D.). D, ThT binding over time by 10 M A42 CR protofibrils, protofibril fractions (F1–F4), and mono-
mers (F5) in supplemented 10 DMEM (96 h of incubation; 37 °C, mean	 S.D.). E–L, representative TEM images of A42 (CR, 0 and 96 h, respectively) (E and
I), F1 (0 and 96 h, respectively) (F and J), F3 (0 and 96 h, respectively) (G and K), and F5 (0 and 96 h, respectively) (H and L) in aliquots of the culture medium
(scale bar 200 nm) are shown. (a.u., arbitrary units; Veh, buffer vehicle.)
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Treatment of cells with preformed F, obtained by incubation
of monomers at the same concentration, also impaired cell
viability by10–20% (p 0.05) but was remarkably less
toxic than crude protofibrils or purified PF.
As observed earlier (Fig. 1D), the A42 CR protofibrils ex-
hibited substantial rise in ThT binding within 24 h (Fig. 2D).
As a control, mature preformed F were also added to the cul-
ture medium and showed a ThT signal similar to crude A42
protofibrils at 24 h. These observations confirmed the sub-
stantial fibrillization of A42 CR during the time interval of
toxicity experiments (24 h). TEM analysis of culture medium
revealed that A42 CR preparations formed extensive mature
fibrils within 24 h (Fig. 2I, compare with the image of pre-
formed fibrils in Fig. 2H). Neither M nor purified PF exhibited
a comparable rise in ThT binding over time (Fig. 2D). This is
consistent with TEM observations that revealed the absence
of mature fibrils in the culture medium and only clusters of
protofibrils after 24 h of incubation (Fig. 2, J and K,
respectively).
Addition of Monomers to Protofibrils Enhances A42 Fibril-
lization and Toxicity—Our results suggest that SEC fraction-
ation of protofibrils reduces, but does not completely elimi-
nate, their toxicity and demonstrate that toxicity of A42
protofibrils is strongly linked to their ability to undergo fibril-
lization and form mature fibrils. Therefore, we wanted to in-
vestigate if the slow fibrillization of protofibrils, and thus their
reduced toxicity, were due to the removal of excess mono-
mers and/or fibrils by SEC. To this end, we reintroduced
A42 monomers, or preformed fibrils, to purified PF (ob-
tained using a Superdex 75 column) or subfractionated proto-
fibril fractions (F1–F4, obtained using a Superose 6 column),
and we assessed the fibrillization and toxicity of each fraction
and mixtures thereof. We hypothesized that the addition of
free monomers and/or preformed fibril seeds would enhance
FIGURE 2. Toxicity of isolated A42monomers, protofibrils, and fibrils toward cultured cells. A, fractionation of A42 CR protofibrils on a Superdex 75
SEC column to separate PF and M. B, analytical SEC of protofibrillar fractions (PF) from A on a Superose 6 pc 3.2/30 column. It is noteworthy that some of the
monomers observed in the PF fractions are due to PF dissociation during the SEC separation. C, cell viability (MTT reduction assay) of cultured rat primary
neurons, PC12 cells, and SHSY5Y cells after 24 h of treatment with 10 M A42 CR, PF, M, and F (one-way ANOVA, n 6 (neurons) and n 9 (PC12 and
SHSY5Y); *, p 0.05; **, p 0.01, mean	 S.D.). D, ThT binding over time by 10 M A42 CR protofibrils, fractionated PF, M, F, and A40 M in supplemented
10 DMEM (24 h of incubation; 37 °C, mean	 S.D.). E–L, representative TEM images of A42 CR (0 and 24 h, respectively) (E and I), A42 PF (0 and 24 h,
respectively) (F and J), A42 M (0 and 24 h, respectively) (G and K), and A42 F (0 and 24 h, respectively) (H and L) in aliquot of the culture medium (scale
bar 200 nm) are shown. (a.u., arbitrary units; Veh, buffer vehicle.)
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both protofibril fibrillization and toxicity. Accordingly, we
observed that reintroduction of A42 monomers to purified
PF resulted in an increase in fibril formation and enhanced
protofibril toxicity (supplemental Fig. 2). To confirm these
findings, we added purified monomers to the subfractionated
A42 protofibrils (F1–F4). Mixtures of monomers and proto-
fibril fractions (F1–F4) exhibited higher ThT binding over
time (Fig. 3A) as compared with fractions containing protofi-
brils only (Fig. 1D). However, it became apparent that the ex-
tent of ThT binding in the monomer/protofibril mixtures was
not as robust as seen in the case of A42 CR (Fig. 1D), sug-
gesting a weak seeding capacity of subfractionated protofi-
brils. Treatment of cells with mixtures of A42 monomers
and subfractionated protofibrils (F1–F4) impaired cell viabil-
ity by25–35% (Fig. 3B, p 0.05), which was comparable
with that seen with A42 crude (40%, Fig. 2C). TEM analy-
sis of the culture medium revealed that addition of A42
monomers to protofibrillar fractions (F1–F4) induced sub-
stantial fibril formation (supplemental Fig. 3, A and B, e.g.
F1M and F3M, respectively, data for F2M and F4M is
not shown). The monomer fraction (F5), after 96 h of incuba-
tion, showed the presence of weakly ThT binding immature
fibrils (Fig. 3A and supplemental Fig. 3C).
Taken together, if A42 fibrillization and toxicity are
closely linked processes, and if these processes require the
availability of Amonomers, then selective degradation of
monomers should significantly retard protofibril elongation
and reduce their toxicity. To examine this hypothesis, we
sought to induce selective removal of A42 monomers using
IDE, an enzyme that selectively degrades Amonomers but
not oligomers or fibrils (31–33). IDE was added to a solution
of A42 monomers, and this mixture was then added to sub-
fractionated protofibril fractions (F1–F4) in supplemented
10 DMEM (see under “Experimental Procedures”). As an-
ticipated, the addition of IDE reversed the effect of A42
monomers in enhancing protofibril toxicity (compare Fig. 3,
C with B). The toxicity of protofibrils (F1–F4) mixed with
IDE-treated A42 monomers was similar to the toxicity seen
with protofibrillar fractions (F1–F4) alone (compare Fig. 3C
with 1C). Similarly, we observed that addition of IDE to toxic
crude A42 preparations resulted in selective degradation of
the monomers and diminished the cytotoxicity and fibrilliza-
tion of these preparations, albeit to a lesser extent than mono-
mer/protofibril mixtures (supplemental Fig. 4).
Next we wanted to determine whether the presence of a
small amount of fibrillar aggregates in the crude preparation,
which might have been lost upon SEC fractionation, also con-
tributed to the enhanced toxicity of this preparation relative
to the SEC-purified protofibrils and monomers. To investi-
gate this, we introduced a small amount (2 M) of sonicated
A42 fibrils (SF) to subfractionated A42 protofibrils (F1–
F4). We found that the addition of sonicated fibrils did not
lead to any significant enhancement of protofibril toxicity
(Fig. 3D), regardless of differences in the size distribution be-
tween the various protofibril fractions. TEM analysis revealed
that, even after 96 h of incubation, these fractions predomi-
nantly contained mixtures of fibrillar seeds and protofibrils
(supplemental Fig. 3, D (F1SF) and E (F3SF)). In contrast,
addition of SF to the monomer fraction (F5) resulted in signif-
icantly increased amyloid formation as evidenced by the pres-
ence of mature fibrils (supplemental Fig. 3F), but the toxicity
was relatively unaffected (Fig. 3D). These findings may indi-
cate that monomer-protofibril interactions, rather than
monomer-fibril interactions, are the key determinant of A42
toxicity. Interestingly, the addition of the mixtures of M and
fibrillar seeds (SF) to the protofibril fractions, and not fibrillar
seeds (SF) only, induced robust toxicity in subfractionated
protofibrils (supplemental Fig. 5B).
FIGURE 3. Effect of monomer addition on fibril formation and toxicity of
subfractionated protofibrils. A, ThT binding over time by 1:1 molar mix-
tures of A42 protofibrils fractions (F1–F5) obtained from Superose 6 with
A42 monomers in supplemented 10 DMEM (10 M A42, 96 h of incuba-
tion; 37 °C, mean	 S.D.). B and C, cell viability (MTT reduction assay) of cul-
tured PC12 and SHSY5Y cells after 24 h of treatment with 1:1 molar mixture
of A42 protofibrils fractions (F1–F5) and A42 monomers (10 M A; one-
way ANOVA, n 9, *, p 0.05; **, p 0.01, mean	 S.D.). C,monomers
were pretreated with IDE before addition to the fractions F1–F5 (A:IDE,
20:1, w/w). D, cell viability (MTT reduction assay) of cultured PC12 and
SHSY5Y cells 24 h after treatment with mixtures of sonicated A42 fibrils (2
M) with SEC protofibrils fractions F1–F5 (8 M) (one-way ANOVA, n 9; *,
p 0.05; **, p 0.01, mean	 S.D.) (CR, crude A42 protofibrils; a.u., arbi-
trary units; Veh, buffer vehicle).
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To determine whether the observed findings are specific to
A42, we carried out fibrillization and toxicity experiments
using different preparations of A40 (crude, monomers,
protofibrils, and mixtures thereof). The data show that at the
concentrations similar to those used in the A42 (5–10 M)
studies, we did not observe significant difference in terms of
toxicity between monomeric, protofibrillar, or crude prepara-
tions of A40 (supplemental Fig. 6). These findings are con-
sistent with the lack of changes in the ThT signal and fibrilli-
zation of these samples, thus supporting our hypothesis that
A toxicity is also linked to its ability to undergo fibril forma-
tion. Consistent with this hypothesis, significant toxicity (30–
40%) was only observed when A40 undergoes fibrillization
(50 M). These findings point to the processes of protofi-
bril-monomer interactions during maturation and elongation
of A protofibrils/oligomers, rather than relatively stable and
discrete oligomers species, as the primary processes that me-
diate A toxicity.
Viability of the Cultured Cells Is Critically Impaired be-
fore the Emergence of Mature A42 Fibrils—To better un-
derstand the relationship between the process of amyloid
formation and A42 toxicity, we treated cultured PC12
cells with A42 CR and sought to correlate the A42 ag-
gregation state in the culture medium with cell viability at
different time points. Fig. 4A shows that A42 CR exhib-
ited a gradual rise in ThT binding within the first 9 h and
then remained relatively unchanged. Interestingly, a grad-
ual and early decline in MTT reduction by A42 CR-
treated cells was also observed during the initial 6 h (Fig.
4B, solid line, 30% decrease compared with time 0, p 
0.01), whereas a significant rise of lactate dehydrogenase in
the culture medium (80%, p  0.005 compared with time
0) was only observed after 6 h of incubation (Fig. 4B,
dashed line). TEM analysis of the culture medium at 3 h
showed clusters of protofibrils and spherical aggregates
(Fig. 4C). At 6 h, the protofibrils were more elongated
and had an immature fibril-like appearance (Fig. 4D). Ma-
ture fibrils started to appear at 9 h (Fig. 4E) and were
more abundant at 24 h (Fig. 4F). These observations sug-
gested that impairment of cell viability, indicated by a de-
cline in the reduction of MTT, a marker for mitochondrial
metabolism (34), was affected by the process of A42
protofibril elongation, in the presence of free monomers,
rather than the formation of mature fibrils. In other words,
toxicity is mediated by nonfibrillar A42 aggregates
formed as a result of an ongoing process of protofibril
elongation, whereas the emergence of mature, high ThT
binding fibrils is a later event.
Crude A42 Preparations, but Not Monomers, Protofibrils,
or Fibrils Alone, Increased Glucose Utilization by Cultured
Astrocytes—We have previously reported that treatment of
cultured astrocytes with A42, at comparable concentrations
as used for cell viability measurements in the experiments
described above, does not induce significant cell death but
alters the astrocyte metabolic activity (25). We observed that
A42 significantly enhances glucose utilization (uptake and
phosphorylation), as assessed by 2-[3H]DG uptake, by cul-
tured astrocytes as compared with A40 (25). We sought to
investigate whether this phenomenon was attributable to
particular A42 assembly state(s) i.e. monomers, protofi-
brils, or fibrils, and/or was influenced by the dynamics of
the A42 aggregation process. Treatment of cultured as-
trocytes with defined A aggregates (fibrils and SEC-puri-
fied monomers and protofibrils) had a negligible effect on
glucose utilization by astrocytes (Fig. 5). However, treat-
ment with an A42 CR preparation, which contained sub-
stantial amounts of protofibril-abundant monomers,
caused a significant (p  0.005) increase in glucose utiliza-
tion (Fig. 5). These observations suggest that the dynamics
of the A42 fibrillization process bear important implica-
tions for not only neuronal viability but also neuron-glia
metabolic coupling in AD pathogenesis.
FIGURE 4. Time course of A42 fibril formation and toxicity. A, ThT bind-
ing over time by 10 M A42 CR protofibrils in DMEM (37 °C; mean	 S.D.).
B, PC12 cell viability (MTT reduction assay and quantification of lactate de-
hydrogenase release in the medium) after treatment with 10 M A42 CR.
For the MTT assay, at the indicated time points, the cultured medium was
completely removed and replaced with MTT assay solution. For lactate de-
hydrogenase release assay, aliquots of the phenol red-free culture medium
were removed from each well at the indicated time points. The data are
expressed as the percentage of the buffer vehicle (Veh) (mean	 S.D.).
C–F, representative TEM images of A42 CR in culture medium aliquots ob-
tained at 3 h (C), 6 h (D), 9 h (E), and 24 h (F) (scale bar in C–F 200 nm).
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DISCUSSION
The identification of toxic A species and/or the process of
their formation is crucial for understanding the mechanism(s)
of A neurotoxicity in AD and development of effective diag-
nostic and therapeutic interventions (35). Several lines of evi-
dence implicate prefibrillar A oligomers, including protofi-
brils, as the primary neurotoxins in AD (9, 36). Aiming to
identify specific toxic A species, we and others have devel-
oped reproducible protocols to isolate prefibrillar aggregates
of defined size and morphology distributions (22, 24, 30).
Herein, we extended our separation protocols to further sub-
fractionate the prefibrillar oligomers and evaluated their
fibrillization and toxicity compared with the monomeric and
fibrillar preparations of A42. We demonstrate that the crude
A42 preparations, containing monomeric and heterogene-
ous mixture of A42 oligomers, are more toxic than purified
monomeric, protofibrillar fractions or fibrils. Subfractionation
of protofibril preparations, to separate different protofibril
species, resulted in further attenuation of their toxicity (Figs.
1 and 2). The diminished toxicity of purified and subfraction-
ated A42 protofibrils was strongly linked to their reduced
fibrillization, thus indicating that A42 toxicity is not neces-
sarily linked to specific prefibrillar aggregate(s) but rather to
the ability of these species to grow in the presence of mono-
meric A42. Consistent with this hypothesis, reintroduction
of monomeric A42 into these fractions restored amyloid
formation and enhanced their toxicity to comparable levels as
observed with the crude preparations. Furthermore, selective
removal of monomeric A42 from these preparations using
IDE reversed the toxicity of A42 protofibrils (Fig. 3). In par-
allel, we demonstrate that the crude A42 preparations were
more potent in inducing metabolic alterations in cultured
astrocytes as compared with the purified monomers, protofi-
brils, and fibrils (Fig. 5). Finally, we also demonstrate that pro-
moting the fibrillization of A40, the major A variant in
vivo, also results in increased cytotoxicity to the cultured cells
(supplemental Fig. 6). Together, these findings provide strong
evidence that A toxicity is linked to an ongoing A polymer-
ization process and is greatly reduced when the polymeriza-
tion process is slowed down by the selective removal/degrada-
tion of Amonomers (Figs. 1–3).
Monomer-Protofibril Interactions Are Key Determinants of
A42 Fibrillization and Toxicity—Consistent with a nucle-
ated polymerization process, the fibrillization of A42 proto-
fibrils, or lack thereof, was strongly influenced by the avail-
ability of monomers. Cell toxicity experiments revealed that
A42 toxicity was enhanced or reduced depending on the
fibrillization propensity of the protofibril or monomer prepa-
rations (Figs. 1–3). This is in agreement with observations
that A variants that exhibit a high aggregation propensity,
e.g. A42 or A-arctic, also induce greater toxicity in cultured
neurons as compared with slower aggregating A variants, e.g.
A40 (37–39). Similarly, accelerating the fibrillogenesis of
soluble A40 preparations by adding exogenous A40 fibrils
also enhances their toxicity (14). Our data suggest that the
fibrillization and toxicity of A42 protofibrils is dependent on
the presence of monomers and not on fibrillar forms of A.
The presence of fibrillar seeds contributes, but is not essen-
tial, to the toxicity seen with mixtures of A42 protofibrils
and monomers (supplemental Fig. 5).
Conversion of A protofibrils into fibrils occurs by incor-
poration of monomers into the growing ends. Therefore, re-
moval of monomers from solution is expected to enhance
protofibril stability and reduce the rate of their fibrillization.
Our findings suggest that kinetic stabilization of protofibrils
would reduce their toxicity. This hypothesis is also supported
by the observations that enhancing the kinetic stability of
A42 protofibrils by the addition of A40 monomers signifi-
cantly reduces their toxicity toward cultured neurons (27).
Similarly, small molecules that stabilize A protofibrils in
vitro have also been shown to improve behavioral perfor-
mance in APP transgenic mice (40). The critical requirement
for Amonomers to maintain A fibrillization, and associ-
ated toxicity in vitro and in vivo, is also underscored by the
overexpression of IDE in APP transgenic animals. These stud-
ies revealed that overexpressing IDE in these animals amelio-
rates plaque pathology, improves behavioral performance,
and prevents premature death (32, 41). Therefore, the con-
centration of monomeric A plays important roles in modu-
lating the amyloid formation and toxicity of A peptides. In-
triguingly, we found that IDE was less efficient at improving
the survival of A42 crude treated cells as compared with the
cells treated with monomer/protofibril mixtures (compare
Fig. 3C with supplemental Fig. 4B). We speculate that this can
possibly result from the preferential incorporation of A42
monomers into protofibrils and/or binding of the IDE to A
oligomers but less efficient degradation due to the secondary
structure elements (42).
The exact mechanisms by which the process of amyloid
formation contributes to A toxicity and neurodegeneration
in AD remain unknown. Our results suggest that the forma-
tion of the toxic A species could occur on site and is medi-
ated by other cellular factors that interact with, or mediate the
interactions between, protofibrils and monomers or respond
to their fibrillization. Given that A species were adminis-
tered extracellularly, it is plausible to postulate that fibrilliza-
tion events take place on the cell membrane where the pro-
cess of amyloid formation triggers downstream intracellular
cascade of events culminating in cell death. This hypothesis is
FIGURE 5. Effect of A42 fibril formation on glucose utilization by cul-
tured astrocytes. 2-[3H]DG utilization by cultured (DIV 21) mouse astro-
cytes after 24 h of treatment with A42 CR protofibrils, F, fractionated PF,
and M (10 M final A concentration). Monomeric A40 (10 M) was in-
cluded for comparison (n 16 from eight independent experiments,
ANOVA followed by a Dunnett’s post hoc test; ***, p 0.005, mean	 S.E.;
Veh, buffer vehicle).
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supported by the findings that association of A to membrane
gangliosides also promotes A fibrillization on the cell surface
and induces toxicity (43). Alternatively, it is also possible that
certain cell surface receptors are activated due to the binding
of protofibrils (44) or their fibrillization, which triggers cellu-
lar pathways compromising neuronal survival capabilities.
In addition to A40, Wogulis et al. (14) also demonstrated
that mixtures of soluble (nonfibrillar) and insoluble (fibrillar)
fractions of IAPP were more toxic to the cultured neurons
than fibrillar and nonfibrillar fractions alone. A recent com-
pelling model for IAPP toxicity directly links the processes of
amyloid aggregation on membrane surfaces with cell-mem-
brane disruption and the onset of toxicity (45, 46). In other
words, as the fibril develops on the membrane surface, the
structural integrity of the membrane is simultaneously com-
promised. In an elegant study, Engel et al. (45) demonstrated
the synchronization of the kinetic profiles for human IAPP-
fibril growth, which was monitored by ThT fluorescence, and
the induction of dye leakage from coincubated mixed 1,2-
dioleoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-
glycero-3-phospho-L-serine vesicles. The two profiles were
characterized by a lag phase of3 h followed by a sigmoidal
transition to human IAPP fibrils and near-complete dye leak-
age from the vesicles. This result indicates that it is the pro-
cess of fibril formation on membrane surfaces that is respon-
sible for abolishing the membrane barrier function. Cryogenic
electron microscopy images of 1,2-dioleoyl-sn-glycero-3-
phosphocholine/1,2-dioleoyl-sn-glycero-3-phospho-L-serine
large unilamellar vesicles coincubated with human IAPP
showed distortion and pinching of regions of the membrane
in contact with fibrils, whereas vesicles incubated in the pres-
ence of nonamyloidogenic mouse IAPP remained unper-
turbed (45). As a mechanistic model, the authors proposed
that IAPP-fibril growth on the membrane occurred concomi-
tantly with a forced change in membrane curvature and weak-
ened lipid packing, which enabled the leakage of intravesicu-
lar contents. Interestingly, this notion is consistent with our
findings, which indicate that it is not one specific oligomeric
state that induces cell death and toxicity but rather the dy-
namic process of fibril formation.
Alternatively, the uptake and internalization of soluble A
(monomers and protofibrils) may impair cellular energy me-
tabolism (intracellular toxicity). This is supported by some
recent reports demonstrating that A in culture medium is
internalized and aggregated intracellularly into fibrils, eventu-
ally causing membrane disruption (47, 48). Further studies are
required to dissect the structural and molecular mechanisms
underlying the critical role of protofibril-monomer interac-
tions in A toxicity. In addition to enhancing neuronal vul-
nerability, the process of A amyloid formation also seems to
interfere with the regulation of glial energy metabolism as
indicated by enhanced glucose utilization by astrocytes (Fig.
5). Importantly, such metabolic changes in astrocytes are as-
sociated with deleterious consequences for neuronal viability
(25) and bear important implications for neuron-glia meta-
bolic coupling (49). Thus, our results demonstrate that accel-
erated A amyloidogenesis triggers a host of mechanisms,
involving both neurons and glia that converge on triggering
neuronal dysfunction and eventual demise.
Implications for Therapies in AD—The possibility that an
ongoing A polymerization process, rather than specific ag-
gregate of defined size or structure, strongly determines A
neurotoxicity has important implications for understanding
the role of A aggregation in AD pathogenesis and the design
of anti-A therapeutics. Our results provide direct evidence
linking A toxicity to the growth and fibrillization of A
oligomers in the presence of Amonomers. These studies
suggest that anti-A therapeutic strategies, many of which are
currently being tested in animal models or in clinical trials in
AD patients, hold potential as promising disease-modifying
interventions. These approaches are based on the following:
1) reducing the production of Amonomers (50–52); 2) se-
questering Amonomers and oligomers to promote their
clearance (53, 54); 3) degrading of Amonomers and
oligomers (41, 55); and 4) preventing A oligomers from sta-
bly binding to the neuronal membranes (40, 56).
Reducing the monomer concentration in vivo is likely to
attenuate A toxicity not only by preventing the formation of
additional toxic oligomers but also by reducing the growth of
circulating oligomers, including protofibrils, and promoting
their clearance from brain. Proof-of-principle experiments
clearly show that even minimal (15%) reduction in mono-
mer A production have profound effects on amyloid pathol-
ogy and related deficits in APP transgenic animals (50–52). In
the absence of free monomers, the unstable nuclei would
cease to grow and possibly disintegrate. Experimental evi-
dence for the latter stipulation can be found in reports show-
ing that sequestration of Amonomers using a small engi-
neered protein (ZA3) (57) led to gradual dissolution of
preexisting oligomers in vitro and promotes amyloid clear-
ance in vivo (57). The administration of therapeutic anti-A
antibodies that sequester Amonomers and oligomers or A
vaccination to generate such antibodies in the host prevents
amyloid formation (53, 58), reduces plaque burden in older
plaque-bearing mice (54, 58), and improves behavioral per-
formance (59, 60).
Development of small molecules that inhibit amyloid for-
mation by stabilizing the monomeric state of A has not been
successful due to the conformational heterogeneity and flexi-
bility of the protein. Our findings suggest that small mole-
cules targeting the growth of oligomers/protofibrils and fi-
brils, by preventing monomer incorporation into the growing
ends of these species, would constitute a more effective strat-
egy to block and/or reverse amyloid formation and toxicity in
vivo. Blocking oligomer growth by capping the ends or bind-
ing to their surfaces can be achieved at substoichiometric lev-
els (27), whereas molecules that stabilize the monomers to
prevent self-assembly would have to be used at stoichiometric
amounts.
Some studies have shown that A immunotherapy im-
proves behavioral performance in APP transgenic animals
without decreasing total (soluble and insoluble) A burden
(59, 61). Although the latter observations seem to challenge
the relevance of the A amyloid cascade hypothesis to AD
pathogenesis, our findings serve to reconcile such discrepan-
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cies and suggest that the amyloid cascade hypothesis has yet
to be disproved. Our data support the notion that a modest
reduction in soluble A (monomers and oligomers) and the
disruption of further nucleation and/or polymerization events
would neutralize protofibril toxicity, facilitate amyloid clear-
ance from brain, and abrogate the spreading of amyloid pa-
thology. In conclusion, targeting the nucleated polymeriza-
tion of amyloid-forming proteins offers an exciting
framework for the development of anti-amyloid therapies for
a host of neurodegenerative diseases characterized by the
pathological accumulation of protein aggregates, including
AD, Parkinson disease, and prion diseases. We hope that
these findings will stimulate further research into understand-
ing the role of the process of amyloid formation in neurode-
generative diseases and the development of in vitro and in
vivomechanistic models to design and evaluate intervention
strategies.
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